CLASS II ONGOING Drug recall · Reported 29 Jul 2026 · FDA Enforcement Report

Levothyroxine Sodium Tablets, USP, 112 mcg 0112 mg) recalled

Major Pharmaceuticals is recalling Levothyroxine Sodium Tablets, USP, 112 mcg 0112 mg) ( unit dose blisters) per, distributed nationwide in the US. The recall was initiated on 13 Jul 2026 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot #: N02203, Exp. Date 09/2026
NDC0904-6949, 0904-6950, 0904-6951, 0904-6952, 0904-6953, 0904-6954
Quantity recalledN/A

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0704-2026
FDA event ID
99399
Recalling firm
Major Pharmaceuticals, Dublin, OH
Manufacturer
Major Pharmaceuticals
Classification
Class II
Status
Ongoing
Recall initiated
13 Jul 2026
FDA classified
17 Jul 2026
Reported
29 Jul 2026
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Potency & Assay

Timeline

13 Jul 2026Recall initiated by company
17 Jul 2026Classified by FDA+4 days
29 Jul 2026Published in enforcement report+12 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Subpotent Drug

Potency and specification recalls happen when a batch tests outside its approved limits for strength, purity or dissolution, which can mean the dose delivered is higher or lower than labelled.

Product as listed by the FDA

Levothyroxine Sodium Tablets, USP, 112 mcg (0.0112 mg), 100 Tablets (10 x 10 unit dose blisters) per carton, Rx only, Packaged and Distributed by: MAJOR PHARMACEUTICALS, Indianapolis, IN 46268 USA. NDC: 0904-6954-61

Where it was distributed

Nationwide in the USA.

Nationwide

Questions about this recall

Is Levothyroxine Sodium Tablets, USP, 112 mcg 0112 mg) ( unit dose blisters) per recalled?

Yes. Major Pharmaceuticals recalled Levothyroxine Sodium Tablets, USP, 112 mcg 0112 mg) ( unit dose blisters) per on 13 Jul 2026. The recall is Class II and its status is Ongoing. Recall number D-0704-2026.

Why was it recalled?

Subpotent Drug

Which lots are affected?

Lot #: N02203, Exp. Date 09/2026

Where was it sold?

Nationwide in the USA.

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Major Pharmaceuticals

All 19

Other Levothyroxine recalls

All 114